drugset / Trial / NCT06500819
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to test the manufacturing feasibility and safety of intravenous (IV) administration of B7-H3CART in children and young adult subjects with relapsed and/or refractory solid tumors expressing B7-H3 target using a standard 3+3 dose escalation design.
Timeline
- Start
- 2024-07-11
- Primary completion
- 2029-07
- Completion
- 2029-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B7-H3CART | Cell therapy | 300000 cells/kg | Intravenous |
| Subject | B7-H3CART | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | B7-H3CART | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | B7-H3CART | Cell therapy | 9e+06 cells/kg | Intravenous |